{"id":"NCT00337428","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED)","officialTitle":"An Open-Label, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of Gardasil (V501) Given Concomitantly With REPEVAX™ in Healthy Adolescents 11-17 Years of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-05","primaryCompletion":"2007-05","completion":"2007-05","firstPosted":"2006-06-16","resultsPosted":"2010-02-11","lastUpdate":"2016-11-16"},"enrollment":843,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Neoplasms, Glandular and Epithelial","Diphtheria","Tetanus","Whooping Cough","Poliomyelitis"],"interventions":[{"type":"BIOLOGICAL","name":"Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Current Manufacturing Facility (CMF)","otherNames":[]},{"type":"BIOLOGICAL","name":"Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Future Manufacturing Facility (FMF)","otherNames":[]},{"type":"BIOLOGICAL","name":"Comparator: REPEVAX™ (Concomitant)","otherNames":[]},{"type":"BIOLOGICAL","name":"Comparator: REPEVAX™ (Non-Concomitant)","otherNames":[]}],"arms":[{"label":"Group 1","type":"EXPERIMENTAL"},{"label":"Group 2","type":"EXPERIMENTAL"},{"label":"Group 3","type":"EXPERIMENTAL"},{"label":"Group 4","type":"EXPERIMENTAL"}],"summary":"Data from this study are expected to demonstrate that Gardasil (V501, Human Papillomavirus \\[Types 6, 11, 16, 18\\] Recombinant Vaccine), when administered concomitantly with a combined diphtheria, tetanus, pertussis, and poliomyelitis vaccine in adolescents remains immunogenic and well-tolerated and it does not impair the immunogenicity of the concomitant vaccines.","primaryOutcome":{"measure":"Geometric Mean Titers (GMTs) for Anti-HPV 6 at Month 7 (4 Weeks Postdose 3)","timeFrame":"Up to 7 Months (4 Weeks Postdose 3)","effectByArm":[{"arm":"qHPV Vaccine + REPEVAX™ (Concomitant)","deltaMin":1151.3,"sd":null},{"arm":"qHPV Vaccine + REPEVAX™ (Non-Concomitant)","deltaMin":1244.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"11 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["19952980"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":420},"commonTop":["Injection site pain-Repevax","Injection site pain-qHPV","Injection site swelling-Repevax","Headache","Injection site swelling-qHPV"]}}